Shares in BARD1 Life Sciences have more than doubled, after the diagnostics business revealed its SubB2M technology can be used to detect all stages of breast cancer.

Shares in BARD1 Life Sciences have more than doubled, after the diagnostics business revealed its SubB2M technology can be used to detect all stages of breast cancer.